Charu 2007.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 287, lymphoma, breast, lung, gastrointestinal, genitourinary, gynecologic, other cancer; no anticancer therapy
Interventions	drug = Darbepoetin alpha dose = 3.0 µg/kg sc Q2W hb‐target = 13‐14 g/dL (women), 13‐15 g/dL (men) planned ESA duration = 12 weeks
Outcomes	Primary: hospitalization days; secondary: costs, QoL, transfusion, Hb, safety
Notes	study number = 53081
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization